

MARKET REPORT



EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Summary

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

- The Acute coronary syndrome (ACS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
- The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The ACS EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global ACS market.
- Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.

<https://www.bioportfolio.co.uk/product/27281-reportstore@bioportfolio.com> to order

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Additional Details

Publisher : Global Data

Reference : GDHCER124-16

Number of Pages : 79

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

- 1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Epidemiology 92.1 Disease Background 92.2 Risk Factors and Comorbidities 102.3 Global Trends 132.3.1 ACS Diagnosed Prevalence 132.3.2 STEMI and NSTEMI Trends 162.3.3 ACS Hospitalizations 182.4 Forecast Methodology 192.4.1 Sources Used 222.4.2 Forecast Assumptions and Methods 292.4.3 Sources Not Used 422.5 Epidemiological Forecast for ACS (2015-2025) 432.5.1 Diagnosed Prevalent Cases of ACS 432.5.2 Age-Specific Diagnosed Prevalent Cases of ACS 462.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS 482.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA 502.5.5 Age-Standardized Diagnosed Prevalence of ACS 522.5.6 ACS Hospitalizations 532.5.7 Sex-Specific ACS Hospitalizations 562.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA 582.6 Discussion 602.6.1 Epidemiological Forecast Insight 602.6.2 Limitations of the Analysis 612.6.3 Strengths of the Analysis 623 Appendix 643.1 Bibliography 643.2 About the Authors 743.2.1 Epidemiologists 743.2.2 Reviewers 743.2.3 Global Director of Therapy Analysis and Epidemiology 763.2.4 Global Head of Healthcare 763.3 About GlobalData 773.4 About EpiCast 773.5 Disclaimer 78

List Of Tables in EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for ACS 12

Table 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants 16

Table 3: 7MM, Sources of Diagnosed Prevalence Data for MI 22

Table 4: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI 24

Table 5: 7MM, Data Sources of ACS Hospitalizations 26

Table 6: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations 28

Table 7: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 45

Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015 47

Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, N (Row %), 2015 49

Table 10: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥ 25 Years, N (Row %), 2015 51

Table 11: 7MM ACS Hospitalizations, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 55

Table 12: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥ 25 Years, N (Row %), 2015 57

Table 13: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥ 25 Years, Both Sexes, N, 2015 59

List Of Figures, Charts and Diagrams in EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

1.2 List of Figures

Figure 1: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008 14

Figure 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%) 16

Figure 3: Case Segmentation Map 22

Figure 4: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 46

Figure 5; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015 48

Figure 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥ 25 Years, N, 2015 50

Figure 7: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥ 25 Years, N, 2015 52

Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥ 25 Years, 2015 53

Figure 9: 7MM ACS Hospitalizations, Ages ≥ 25 Years, Both Sexes, N, Select Years, 2015-2025 56

Figure 10: 7MM, Sex-Specific ACS, Ages ≥ 25 Years, N, 2015 58

Figure 11: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥ 25 Years, Both Sexes, N, 2015 60

How to Buy...

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27281>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.